Scotland told not to allow Rx top ups

14 September 2008

Bowel Cancer UK, a registered charity, has told the Scottish government it should not allow patients who are denied prescription drugs by the National Health Service to pay for them out of their own pocket. Ian Beaumont, the communications director for the group, claimed that "any move towards a co-payments system in Scotland, however well-intentioned, will have a negative effect on patients." Nevertheless, the group also stated that the existing methodology used by the National Institute for Health and Clinical Excellence (NICE) to determine which drugs should be available to patients outside Scotland was flawed and should allow more patient access to new therapies.

The Financial Times reports that Scotland's Deputy First Minister, Nicola Sturgeon, who is responsible for health care at the Cabinet level, wrote to the Scottish Parliament that "there may be a case" for co-payments.

The UK government is considering the issue of allowing patients to pay for drugs without losing NHS coverage, which they pay for in taxation, with a review expected to announce recommendations later this year. The Scottish Medicines Authority, which recommends which drugs should available to NHS patients in Scotland, is also examining the principles that should govern the prescribing and funding of medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight